Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis : Episode 9
Advanced Treatment Options for RA: Exploring the Data
Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).
EP: 1.Intro and Welcomes
EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations
EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
Now Viewing
EP: 9.Advanced Treatment Options for RA: Exploring the Data
EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
EP: 11.JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety
EP: 12.JAK Inhibitor Selectivity and Dose-Related Toxicity
Video content above is prompted by the following:
Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission.
- Please discuss the SELECT-COMPARE trial head-to-head data on upadacitinib vs adalimumab.
- Please discuss the use of upadacitinib for active RA refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND trial).
- What are the remission rates seen with upadacitinib vs abatacept (SELECT-CHOICE trial)?
Recent Videos
Related Content
